Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (2410)	8/13/1998 4:29:00 PM
From: john dixon	Read Replies (1) \| Respond to of 3702

Davis, I appreciate your and Golfdads comments. That being said, as far as a "family", lets let each person owning tcln decide what the "family" is. If each stockholder was told tomorrow for a fact, you can have a cure for cancer or $1000.00 per share for your stock. Well, you get the picture, the family splits. I know I will catch hell for this post but I buy stock to make money, period! I BELIEVE tcln will be a BIG winner and in turn also cancer patients. john PS: I make donations to the American Cancer Society every year, that is fighting cancer, not investing in the market.

To: EZLibra who wrote (2410)	8/13/1998 9:12:00 PM
From: Tim K	Read Replies (1) \| Respond to of 3702

The posts on the CLTR thread about TCLN illustrate why TCLN doesn't have a higher share price (yet). All one needs to do is go to the Yahoo quote/profile pages and you'll see: Cash: $.09 per share - $3.77 million total. Further due diligence reveals $3million/qrtr burn rate, $72million in debt. Compare this to the other biotechs out there like ENMD and CLTR and at first glance, at least based on the financials, it isn't a prudent investment. This isn't brain surgery (excuse the pun). It will take better financials, or a blockbuster treatment success announcement to get the average investor to take the risk. Those of us who have researched the technology and its potential and see the positive things current management is doing, the advances in the clinicals, and financial improvements are willing to take the risk. I think we will be well rewarded. Davis - you represent us well. To bad golfdad doesn't want to be quoted - even the competition respects him. Tim K